Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission

PHASE2CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

March 5, 2015

Primary Completion Date

March 27, 2018

Study Completion Date

August 24, 2023

Conditions
Neuroblastoma
Interventions
DRUG

DFMO

Subjects will receive twenty-seven (27) cycles of oral DFMO at a dose of 500 to 1000 mg/m2 BID on each day of a 28 day cycle.

Trial Locations (22)

10467

The Children's Hospital at Montefiore, The Bronx

17033

Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey

28204

Levine Children's Hospital, Charlotte

29425

Medical University of South Carolina, Charleston

32806

Arnold Palmer Hospital for Children, Orlando

33701

All Children's Hospital Johns Hopkins Medicine, St. Petersburg

37232

Monroe Carrell Jr. Children's Hospital at Vanderbilt, Nashville

43205

Nationwide Children's Hospital, Columbus

49503

Helen DeVos Children's Hospital, Grand Rapids

55404

Children's Hospital and Clinics on Minnesota, Minneapolis

63104

Cardinal Glennon Children's Medical Center, St Louis

64108

Children's Mercy Hospitals and Clinics, Kansas City

72202

Arkansas Children's Hospital, Little Rock

75235

Children's Medical Center, Dallas

77030

Texas Children's Cancer and Hematology Centers, Houston

78723

Dell Children's Blood and Cancer Center, Austin

84113

Primary Children's Hospital, Salt Lake City

85016

Phoenix Children's Hospital, Phoenix

92123

Rady Children's Hospital, San Diego

96813

Kapiolani Medical Center for Women and Children, Honolulu

06106

Connecticut Children's Hospital, Hartford

02111

Tufts Medical Center, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Beat NB Cancer Foundation

OTHER

collaborator

Because of Ezra

OTHER

collaborator

K C Pharmaceuticals Inc.

INDUSTRY

lead

Giselle Sholler

OTHER